eligibility_summary
Eligible: measurable relapsed/refractory non-Hodgkin lymphoma without effective options, or relapsed/refractory multiple myeloma previously exposed to PI, IMiD, and anti‑CD38, ECOG 0–2, adequate hematologic, hepatic, renal, and coagulation function. Exclude: plasma cell leukemia/POEMS, CNS disease, significant cardiovascular disease, chronic steroids >20 mg prednisone, recent RT/HSCT/other anticancer therapy, prior anti‑CD47/SIRPα, other trials, active infections, active GVHD.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05896774 (Phase 1, China). Intervention: Maplirpacept (PF-07901801, TTI‑622), an engineered SIRPα–IgG4 Fc fusion protein (biologic, myeloid checkpoint inhibitor) given IV weekly as monotherapy. Mechanism of action: Binds and sequesters CD47 on tumor cells, blocking the CD47–SIRPα “don’t‑eat‑me” signal, thereby releasing macrophage inhibition and promoting antibody‑Fc receptor–mediated phagocytosis, designed with IgG4 Fc to reduce off‑target cytotoxicity (e.g., anemia) while retaining pro‑phagocytic Fc engagement. Targets/cells/pathway: CD47 on malignant B cells/plasma cells, SIRPα on macrophages/monocytes, activates innate immune phagocytosis and antigen presentation pathways (myeloid checkpoint). Indications: relapsed/refractory non‑Hodgkin lymphoma and multiple myeloma. Primary aims: pharmacokinetics, safety, and preliminary anti‑tumor activity.